Drug intelligence / Profile preview

isoginkgetin

Development stage
Preclinical
Modality
Small Molecules
Administration
Intravenous
01

Overview

**Isoginkgetin** is a naturally occurring biflavonoid compound derived from Ginkgo biloba leaves, structurally composed of two apigenin units linked by a 3',8'' carbon-carbon bond. It acts as a small molecule inhibitor of several key biological proteins, notably functioning as a potent inhibitor of ATP-citrate lyase (ACLY), thereby reducing lipid synthesis and exhibiting lipid-lowering effects. Mechanistically, isoginkgetin is also known as a general inhibitor of pre-mRNA splicing as it targets spliceosome assembly. In cancer research, isoginkgetin inhibits matrix metalloproteinase 9 (MMP-9), reduces tumor growth in animal models, and has demonstrated effects as a CDK6 inhibitor and as an enhancer of tumor antigen presentation. It also shows anti-inflammatory actions, e.g., suppressing iNOS in activated microglia and reversing lipopolysaccharide-induced depression-like and pro-inflammatory responses in animal models.

Other names
iso-ginkgetin4',4'''-Dimethylamentoflavone4',4'''-Dimethoxyamentoflavone
02

Targets

MMP9 (Matrix metalloproteinase-9)CDK6 (Cyclin-dependent kinase 6)spliceosome (NineTeen Complex)ACLY (ATP-citrate synthase)

Beyond the preview

Go deeper on isoginkgetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoginkgetin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call